Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCINASDAQ:CTXRNASDAQ:GELSNASDAQ:NTBL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$3.40-2.6%$3.45$1.96▼$6.77$10.71M0.7411,649 shs1,751 shsCTXRCitius Pharmaceuticals$1.08+18.3%$0.84$0.65▼$26.25$11.48M0.87655,739 shs2.90 million shsGELSGelteq$1.60-11.6%$1.75$0.77▼$5.50$15.10MN/A4.00 million shs60,982 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma0.00%-4.79%-4.25%+5.56%+339,899,900.00%CTXRCitius Pharmaceuticals0.00%+23.49%+53.63%-30.32%-92.91%GELSGelteq0.00%-23.81%-11.11%+53.85%+159,999,900.00%NTBLNotable Labs0.00%0.00%0.00%0.00%-64.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACTXRCitius Pharmaceuticals2.0184 of 5 stars3.42.00.00.01.10.81.3GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/ACTXRCitius Pharmaceuticals 2.80Moderate Buy$54.504,946.30% UpsideGELSGelteq 0.00N/AN/AN/ANTBLNotable Labs 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest NTBL, CTXR, CSCI, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.59M1.12N/AN/A$3.49 per share0.97CTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AGELSGelteq$100K151.04N/AN/AN/A∞NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.000.86N/AN/A-58.63%-37.67%8/11/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/ANTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ALatest NTBL, CTXR, CSCI, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A2.882.54CTXRCitius PharmaceuticalsN/A0.370.06GELSGelteqN/AN/AN/ANTBLNotable Labs0.032.772.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%CTXRCitius Pharmaceuticals16.88%GELSGelteqN/ANTBLNotable Labs70.48%Insider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%CTXRCitius Pharmaceuticals10.70%GELSGelteqN/ANTBLNotable Labs1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.15 million3.14 millionN/ACTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableGELSGelteqN/A9.44 millionN/AN/ANTBLNotable Labs409.02 million9.54 millionNo DataNTBL, CTXR, CSCI, and GELS HeadlinesRecent News About These CompaniesNotable Labs, Ltd. (NTBLQ)February 13, 2025 | finance.yahoo.comWhat Factors Have Led to Notable Labs Ltd (NTBL) Stock Trading -93.03% Below Its 52-Week High?October 22, 2024 | bovnews.comNotable Labs Ltd (NTBL) Stock: Greater Than Its Current Valuation?October 18, 2024 | bovnews.comNotable Labs files for bankruptcy, ending ambitions for Boehringer cancer drugOctober 16, 2024 | fiercebiotech.comNotable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces LayoffsSeptember 20, 2024 | marketwatch.comNotable Labs (NTBL) was downgraded to a Hold Rating at JMP SecuritiesSeptember 20, 2024 | markets.businessinsider.comNotable Labs to Present Data on September 4th at SOHO 2024August 29, 2024 | globenewswire.comNotable Labs Announces CEO TransitionAugust 27, 2024 | finance.yahoo.comNTBL Stock Earnings: Notable Labs Misses EPS for Q2 2024August 16, 2024 | investorplace.comLA’s best burrito is a lab-engineered marvelAugust 15, 2024 | msn.comNotable Labs: Q2 Earnings SnapshotAugust 15, 2024 | sfgate.comNotable Labs, Ltd. (NTBL)July 26, 2024 | finance.yahoo.comIt’s Better to Hope for Prosperity than Become Adversary: Notable Labs Ltd (NTBL) StockJuly 25, 2024 | bovnews.comNotable Labs Cleared by FDA to Begin Phase II Trial of Volasertib in AMLJuly 24, 2024 | precisionmedicineonline.comNotable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyJuly 24, 2024 | globenewswire.comNPC Labs raises $18M to bring mainstream games to Web3July 22, 2024 | venturebeat.comBears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' NowMay 24, 2024 | zacks.comOppenheimer raised the price target for the Notable Labs Ltd (NASDAQ:NTBL) stock to “”a Perform””May 24, 2024 | bovnews.comNTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024May 16, 2024 | investorplace.comBuy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP PlatformMay 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, CTXR, CSCI, and GELS Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCI$3.40 -0.09 (-2.61%) Closing price 06/20/2025 03:57 PM EasternExtended Trading$3.40 +0.00 (+0.03%) As of 06/20/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Citius Pharmaceuticals NASDAQ:CTXR$1.08 +0.17 (+18.34%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.12 +0.04 (+4.17%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Gelteq NASDAQ:GELS$1.60 -0.21 (-11.60%) As of 06/20/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
